Aerpio Pharmaceuticals (OTCMKTS:ARPO) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Aerpio Pharmaceuticals (OTCMKTS:ARPO) posted its quarterly earnings results on Thursday. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.01, Fidelity Earnings reports.

Shares of ARPO opened at $0.54 on Friday. The company’s 50 day simple moving average is $0.58 and its 200-day simple moving average is $0.80. Aerpio Pharmaceuticals has a 12-month low of $0.45 and a 12-month high of $4.25.

Several equities research analysts have recently commented on ARPO shares. HC Wainwright set a $1.00 price target on shares of Aerpio Pharmaceuticals and gave the company a “hold” rating in a report on Monday, October 21st. Zacks Investment Research raised shares of Aerpio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a report on Wednesday, October 9th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $3.25.

Aerpio Pharmaceuticals Company Profile

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.

Recommended Story: Range Trading

Earnings History for Aerpio Pharmaceuticals (OTCMKTS:ARPO)

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.